Apellis Pharmaceuticals

Apellis Pharmaceuticals is a biopharmaceutical company based in Waltham, Massachusetts, founded in 2009. The company specializes in developing targeted therapies that inhibit the complement system, particularly focusing on the central protein C3. This innovative approach aims to treat a variety of serious diseases by managing the overactivation of the complement system, which can harm healthy cells and tissues. Apellis has successfully advanced two first-in-class C3-targeting medicines: EMPAVELI, an injection approved for treating paroxysmal nocturnal hemoglobinuria (PNH), and SYFOVRE, approved for geographic atrophy (GA) secondary to age-related macular degeneration. The company also works on treatments for rare kidney diseases, including C3 glomerulopathy and primary immune complex-mediated membranoproliferative glomerulonephritis. With a commitment to improving patient outcomes, Apellis continues to leverage its expertise in complement science to develop new therapies for serious conditions. The company employs around 705 people and is dedicated to innovation in complement-based therapies.